Genitourinary Malignancies in Transplant or Dialysis Patients: The Frequency of Two Newly Described 2016 World Health Organization Histopathologic Types

Billis, Athanase; Freitas, Leandro Luiz Lopes de; Costa, Larissa Bastos Eloy da; Barreto, Icléia Siqueira; Asato, Marcel Arakaki; Araujo, Karina S.; Losada, Daniele Moraes; Tabosa, Gabriel V. B. S.; Zaidan, Bruna Cunha; Oliveira, Gabriela; Bastos, Lucas Q. A.

doi:10.1016/j.transproceed.2017.06.035

Cited by 4 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the group of patients with ESRD-RCC we found significantly more papillary and chromophobe RCCs. Our results are consistent with the histopathological distributions that have been previously reported [8,9,14,15,17,25]. The main hypothesis for explaining the RCC type in ESRD patients is based on the fact that ACKD incidence increases over time, with dialysis reaching almost 90% over 5-10 years [9,13,24].…”

Section: Discussionsupporting

confidence: 92%

Increased risk for renal cell carcinoma in end stage renal disease – a population-based case-control study

Akerlund

Holmberg

Lindblad

et al. 2021

Scandinavian Journal of Urology

View full text Add to dashboard Cite

Purpose: End-stage renal disease (ESRD) is a known risk factor for the development of renal cell carcinoma (RCC). This case-control study was performed to assess the risk in a nationwide cohort and evaluate tumor characteristics and survival in the ESRD-RCC population. Methods: In this study, 9,299 patients with RCC identified in the National Swedish Kidney Cancer Register from 2005 until 2014 and 93,895 matched controls were linked to the Swedish Renal Registry and the National Patient Register. ESRD was defined as chronic kidney disease stage 5, kidney transplantation or kidney dialysis 0-40 years before the diagnosis of RCC. Results: A total of 117 patients with ESRD and subsequent RCC were identified and compared with 9,087 patients with RCC. There was a 4.5-times increased risk for RCC among ESRD patients (95% CI ¼ 3.6-5.6; p < 0.001) compared to matched controls. Longer time with ESRD increased the risk of RCC (ESRD > 9 years, OR ¼ 10.2, 95% CI ¼ 7.0-14.8). The ESRD-RCC patients were younger (p ¼ 0.002), had smaller tumors (p < 0.001) and had lower tumor stage (p ¼ 0.045). The incidence of papillary and chromophobe RCC was higher and clear cell RCC lower among the ESRD patients (p < 0.001). The 5-year overall survival was 50% in ESRD-RCC patients and 63% in RCC-only patients (p < 0.05). Conclusion: More than 9 years with ESRD increased the risk of developing RCC 10-times compared to individuals without ESRD and the tumors showed a different histopathological pattern. Despite a less advanced tumor stage at diagnosis, the overall survival in ESRD-RCC patients was lower compared to patients with RCC-only.

show abstract

Section: Discussionsupporting

confidence: 92%

Increased risk for renal cell carcinoma in end stage renal disease – a population-based case-control study

Akerlund

Holmberg

Lindblad

et al. 2021

Scandinavian Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Notably, malignancies after kidney transplantation are predominantly reported in native kidneys [32]. Papillary renal cell carcinoma remains the most common type of cancer in patients with advanced kidney disease receiving haemodialysis [33]. Atypical localization and histological type of renal carcinoma found in our patient after kidney transplantation highlight the need for diagnostic awareness in patients presenting GBS symptoms.…”

Section: Discussionmentioning

confidence: 79%

Guillain-Barre syndrome: a typical paraneoplastic syndrome in a kidney transplant recipient with allograft renal cell carcinoma: a case report and review of the literature

et al. 2020

View full text Add to dashboard Cite

Background Guillain-Barré syndrome (GBS) is an autoimmune polyneuropathy affecting the peripheral nervous system. This neurological disorder has been previously reported in bone marrow transplant recipients but is uncommon after kidney transplantation. Viral infections and calcineurin inhibitors are the main triggers of GBS in renal transplant recipients. Case presentation In this report, we present a case of a 47-year-old male patient 12 years after his second kidney transplantation who developed GBS due to papillary renal cell carcinoma. Infectious and drug-related origins of GBS were excluded. Despite intensive treatment, graftectomy was performed, after which neurological symptoms resolved. Conclusions In kidney transplant recipients, paraneoplastic aetiology should be considered in the differential diagnosis of GBS.

show abstract

Management of renal cell carcinoma in transplant kidney: a systematic review and meta-analysis

Crocerossa

Autorino

Derweesh

et al. 2023

Minerva Urol Nephrol

View full text Add to dashboard Cite

Genitourinary Malignancies in Transplant or Dialysis Patients: The Frequency of Two Newly Described 2016 World Health Organization Histopathologic Types

Cited by 4 publications

References 11 publications

Increased risk for renal cell carcinoma in end stage renal disease – a population-based case-control study

Increased risk for renal cell carcinoma in end stage renal disease – a population-based case-control study

Guillain-Barre syndrome: a typical paraneoplastic syndrome in a kidney transplant recipient with allograft renal cell carcinoma: a case report and review of the literature

Management of renal cell carcinoma in transplant kidney: a systematic review and meta-analysis

Contact Info

Product

Resources

About